Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

Getting below the surface: regional and local market access

Gaining access to a national market is a key hurdle in a drug’s life cycle, as is getting through the maze of the different health technology assessments (HTAs) and pricing...

- PMLiVE

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Option to acquire the Austrian biotech after phase I trials remains open to Boehringer 

- PMLiVE

Grünenthal research consortium receives €1.5m EU grant

Wins funding for development of efficacy testing in neuropathic pain treatments

Deal Watch August 2016

Pfizer's hat trick as well as Sanofi, GlaxoSmithKline, Boehringer Ingelheim and more are featured in this month's round-up

- PMLiVE

Boehringer to add wireless data-collection to its Respimat inhaler

Joins forces with Qualcomm for COPD adherence collaboration

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

Sanofi reception

EC approves Sanofi’s deal for Boehringer’s consumer business

Regulator passes the acquisition, subject to the French firm divesting some products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links